Lund based Iconovo did not sit still during the summer, instead the company released the biggest news of the year thus far. in mid-July, Iconovo  announced that a clinical pharmacokinetics study had established that Iconovo’s ICOres budesonide/formoterol is working according to expectations.
The positive results led Erik Penser Bank to increase its motivated value of Iconovo from 360 MSEK to 410 MSEK, supporting the company’s confidence in the product. Read more